美迈斯助力2023年首家18A生物科技公司绿竹生物完成4,300万美元香港上市
香港，2023年5月8日——美迈斯近日代表北京绿竹生物技术股份有限公司（香港股份代号：2480）（“绿竹生物”）完成其首次公开发行及香港联合交易所主板上市。绿竹生物此次发行规模约为3.4亿港元（约合4,300万美元）。如超额配售选择权完全行使，绿竹生物的发行规模将达到约3.92亿港元（约合5,000万美元）。美迈斯担任绿竹生物的美国及香港律师，并主笔撰写其招股书。这是2023年首家18A生物科技公司香港上市，也是美迈斯近年来成功完成的第15个18A生物科技公司香港上市项目，进一步巩固了本所在这一领域的领先地位。
绿竹生物于2001年在北京成立，是一家致力于开发创新型人类疫苗和治疗性生物制剂，以预防和控制传染性疾病，并治疗癌症和自身免疫性疾病的生物技术公司。绿竹生物专注于人类医学领域，并凭借对免疫学和蛋白质工程的理解，建立了技术平台，令其可开发效率优良、高纯度及稳定性有所改善的重组疫苗及抗体在研产品。其产品管线包括三款临床阶段的在研产品以及四款临床前阶段的在研产品，其中核心产品为LZ901。LZ901是其自主开发的具有四聚体分子结构的在研重组带状疱疹疫苗，用于预防年龄为50岁及以上成人水痘带状疱疹病毒引起的带状疱疹。
中国国际金融香港证券有限公司担任此次首次公开发行的独家保荐人、独家整体协调人及独家代表。
参与本交易的美迈斯团队由公司业务合伙人朱柯和耿科领导，核心团队成员包括资深律师刘伟，律师王玥、古兆弘和邓超，以及法律顾问李声瑶、骆鑫和陈超然。合伙人黄凯德（Kurt Berney）就美国法律意见相关问题提供咨询意见。
HONG KONG, MAY 8, 2023 —O’Melveny recently represented Beijing Luzhu Biotechnology Co., Ltd. (“Luzhu Biotech”) (2480.HK) in its initial public offering and listing of H shares on the Main Board of the Hong Kong Stock Exchange. The IPO offering size was approximately HK$340 million (approximately US$43 million). Assuming full exercise of the over-allotment option, the offering size will be approximately HK$392 million (approximately US$50 million). O’Melveny advised Luzhu Biotech on both U.S. and Hong Kong laws and drafted its prospectus. This transaction, which is the first Hong Kong IPO of a 18A biotech company in 2023, also marks O’Melveny’s 15th Hong Kong IPO completed for Chapter 18A biotech companies, further solidifying the firm’s leading position in this field.
Founded in Beijing in 2001, Luzhu Biotech is a biotechnology company committed to developing innovative human vaccines and therapeutic biologics to prevent and control infectious diseases and treat cancer and autoimmune diseases. Luzhu Biotech focuses on human medicine and has established technology platforms with its understanding of immunology and protein engineering, which empowers it to develop its recombinant vaccine and antibody product candidates with favorable efficiency, high purity and improved stability. Its product pipeline consists of three clinical-stage product candidates and four pre-clinical-stage product candidates, among which, the core product LZ901, an independently developed recombinant herpes zoster vaccine candidate, has a tetrameric molecular structure to prevent shingles caused by varicella-zoster virus for adults aged 50 years and older.
China International Capital Corporation Hong Kong Securities Limited acted as the Sole Sponsor, Sole Overall Coordinator and Sole Representative for this transaction.
The O’Melveny team for this transaction was led by corporate partners Ke Zhu and Ke Geng, with assistance from counsel Wei Liu, associates Katherine Wang, Edward Ku and Rita Deng, and legal consultants Madlyn Li, Michelle Luo and Chaoran Chen. Partner Kurt Berney provided U.S. legal opinion related advice.
主要联系人/Key Contacts